Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473 is registered in ClinicalTrials.gov with MoonLake Immunotherapeutics AG as lead sponsor.

NCT NCT05322473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
MoonLake Immunotherapeutics AG
Phase
Phase 2
Overall status
Completed
Start date
April 25, 2022
Completion date
August 30, 2023
Enrollment
234 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa